Literature DB >> 17591968

TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions.

Nigel J Cairns1, Manuela Neumann, Eileen H Bigio, Ida E Holm, Dirk Troost, Kimmo J Hatanpaa, Chan Foong, Charles L White, Julie A Schneider, Hans A Kretzschmar, Deborah Carter, Lisa Taylor-Reinwald, Katherine Paulsmeyer, Jeffrey Strider, Michael Gitcho, Alison M Goate, John C Morris, Manjari Mishra, Linda K Kwong, Anna Stieber, Yan Xu, Mark S Forman, John Q Trojanowski, Virginia M-Y Lee, Ian R A Mackenzie.   

Abstract

TAR DNA-binding protein 43 (TDP-43) is a major pathological protein of sporadic and familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions (FTLD-U) with or without motor neuron disease (MND). Thus, TDP-43 defines a novel class of neurodegenerative diseases called TDP-43 proteinopathies. We performed ubiquitin and TDP-43 immunohistochemistry on 193 cases of familial and sporadic FTLD with or without MND. On selected cases, immunoelectron microscopy and biochemistry were performed. Clinically defined frontotemporal dementias (FTDs) included four groups: 1) familial FTD with mutations in progranulin (n = 36), valosin-containing protein (n = 5), charged multivesicular body protein 2B (n = 4), and linked to chromosome 9p (n = 7); 2) familial cases of FTD with unknown gene association (n = 29); 3) sporadic FTD (n = 72); and 4) familial and sporadic FTD with MND (n = 40). Our studies confirm that the spectrum of TDP-43 proteinopathies includes most cases of sporadic and familial FTLD-U with and without MND and expand this disease spectrum to include reported families with FTD linked to chromosome 9p but not FTD with charged multivesicular body protein 2B mutations. Thus, despite significant clinical, genetic, and neuropathological heterogeneity of FTLD-U, TDP-43 is a common pathological substrate underlying a large subset of these disorders, thereby implicating TDP-43 in novel and unifying mechanisms of FTLD pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17591968      PMCID: PMC1941578          DOI: 10.2353/ajpath.2007.070182

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  48 in total

Review 1.  Consensus statement on the diagnosis of multiple system atrophy.

Authors:  S Gilman; P A Low; N Quinn; A Albanese; Y Ben-Shlomo; C J Fowler; H Kaufmann; T Klockgether; A E Lang; P L Lantos; I Litvan; C J Mathias; E Oliver; D Robertson; I Schatz; G K Wenning
Journal:  J Neurol Sci       Date:  1999-02-01       Impact factor: 3.181

2.  Alpha-synuclein in Lewy bodies.

Authors:  M G Spillantini; M L Schmidt; V M Lee; J Q Trojanowski; R Jakes; M Goedert
Journal:  Nature       Date:  1997-08-28       Impact factor: 49.962

3.  Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia.

Authors:  Gaia Skibinski; Nicholas J Parkinson; Jeremy M Brown; Lisa Chakrabarti; Sarah L Lloyd; Holger Hummerich; Jørgen E Nielsen; John R Hodges; Maria Grazia Spillantini; Tove Thusgaard; Sebastian Brandner; Arne Brun; Martin N Rossor; Anders Gade; Peter Johannsen; Sven Asger Sørensen; Susanne Gydesen; Elizabeth M C Fisher; John Collinge
Journal:  Nat Genet       Date:  2005-07-24       Impact factor: 38.330

Review 4.  The neuropathology of CAG repeat diseases: review and update of genetic and molecular features.

Authors:  Y Robitaille; I Lopes-Cendes; M Becher; G Rouleau; A W Clark
Journal:  Brain Pathol       Date:  1997-07       Impact factor: 6.508

Review 5.  Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.

Authors: 
Journal:  Neurobiol Aging       Date:  1997 Jul-Aug       Impact factor: 4.673

6.  Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies.

Authors:  M G Spillantini; R A Crowther; R Jakes; N J Cairns; P L Lantos; M Goedert
Journal:  Neurosci Lett       Date:  1998-07-31       Impact factor: 3.046

7.  Neuropathological diagnosis and CAG repeat expansion in Huntington's disease.

Authors:  J H Xuereb; J C MacMillan; R Snell; P Davies; P S Harper
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-01       Impact factor: 10.154

Review 8.  Diagnostic criteria for Parkinson disease.

Authors:  D J Gelb; E Oliver; S Gilman
Journal:  Arch Neurol       Date:  1999-01

9.  Depletion of TDP 43 overrides the need for exonic and intronic splicing enhancers in the human apoA-II gene.

Authors:  Pablo Arrisi Mercado; Youhna M Ayala; Maurizio Romano; Emanuele Buratti; Francisco E Baralle
Journal:  Nucleic Acids Res       Date:  2005-10-27       Impact factor: 16.971

10.  Human, Drosophila, and C.elegans TDP43: nucleic acid binding properties and splicing regulatory function.

Authors:  Youhna M Ayala; Sergio Pantano; Andrea D'Ambrogio; Emanuele Buratti; Antonia Brindisi; Caterina Marchetti; Maurizio Romano; Francisco E Baralle
Journal:  J Mol Biol       Date:  2005-05-06       Impact factor: 5.469

View more
  206 in total

1.  Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: the essential role of the neuropathology core.

Authors:  Nigel J Cairns; Lisa Taylor-Reinwald; John C Morris
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

2.  Wild type TDP-43 induces neuro-inflammation and alters APP metabolism in lentiviral gene transfer models.

Authors:  Alexander M Herman; Preeti J Khandelwal; G William Rebeck; Charbel E-H Moussa
Journal:  Exp Neurol       Date:  2012-02-28       Impact factor: 5.330

Review 3.  Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration.

Authors:  Edward B Lee; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurosci       Date:  2011-11-30       Impact factor: 34.870

4.  Coexisting adult polyglucosan body disease with frontotemporal lobar degeneration with transactivation response DNA-binding protein-43 (TDP-43)-positive neuronal inclusions.

Authors:  Jill G Farmer; Barbara J Crain; Brent T Harris; R Scott Turner
Journal:  Neurocase       Date:  2012-04-16       Impact factor: 0.881

Review 5.  Advances in understanding the molecular basis of frontotemporal dementia.

Authors:  Rosa Rademakers; Manuela Neumann; Ian R Mackenzie
Journal:  Nat Rev Neurol       Date:  2012-06-26       Impact factor: 42.937

Review 6.  TAR DNA-binding protein 43 in neurodegenerative disease.

Authors:  Alice S Chen-Plotkin; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurol       Date:  2010-03-16       Impact factor: 42.937

7.  TDP-43 pathology in a case of hereditary spastic paraplegia with a NIPA1/SPG6 mutation.

Authors:  Maria Martinez-Lage; Laura Molina-Porcel; Dana Falcone; Leo McCluskey; Virginia M-Y Lee; Vivianna M Van Deerlin; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2012-08       Impact factor: 17.088

Review 8.  The genetics of frontotemporal lobar degeneration.

Authors:  Rosa Rademakers; Mike Hutton
Journal:  Curr Neurol Neurosci Rep       Date:  2007-09       Impact factor: 5.081

9.  VCP mutations causing frontotemporal lobar degeneration disrupt localization of TDP-43 and induce cell death.

Authors:  Michael A Gitcho; Jeffrey Strider; Deborah Carter; Lisa Taylor-Reinwald; Mark S Forman; Alison M Goate; Nigel J Cairns
Journal:  J Biol Chem       Date:  2009-02-23       Impact factor: 5.157

10.  Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration.

Authors:  Nigel J Cairns; Eileen H Bigio; Ian R A Mackenzie; Manuela Neumann; Virginia M-Y Lee; Kimmo J Hatanpaa; Charles L White; Julie A Schneider; Lea Tenenholz Grinberg; Glenda Halliday; Charles Duyckaerts; James S Lowe; Ida E Holm; Markus Tolnay; Koichi Okamoto; Hideaki Yokoo; Shigeo Murayama; John Woulfe; David G Munoz; Dennis W Dickson; Paul G Ince; John Q Trojanowski; David M A Mann
Journal:  Acta Neuropathol       Date:  2007-06-20       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.